Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Jonathan Strober, MD, explains the initial presentation of myasthenia gravis in a pediatric patient population and why initial diagnosis for these patients can be challenging.

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...

Beyond the pandemic, policymakers must cooperate to resolve trade and technology tensions that endanger an eventual recovery from the COVID-19 crisis. Furthermore, building on the record drop in ...

Working Papers describe research in progress by the author(s) and are published to elicit comments and to further debate This paper tells the story of the Asian financial crisis by addressing four ...

If you have swollen, red, and crusty eyelids, you may have blepharitis. “Blepharitis” is the medical term for eyelid inflammation. While uncomfortable, blepharitis is considered a common ...

Ukraine needs 500 million euros to rebuild critical port facilities damaged by Russia Ukraine needs an initial 500 million euros ($566 million) to rebuild the most important infrastructure ...

Purpose: The stability of a triamcinolone acetonide mouthwash and its efficacy in treating oral lichen planus are described. Results: The mouthwash had a satisfactory shelf life and was well ...

Medscape News has partnered with Retraction Watch to provide news about scientific fraud and integrity. Retraction Watch is a project of the nonprofit Center For Scientific Integrity dedicated to ...

Trump says Russia’s Vladimir Putin is ‘playing with fire’ and Russia has so far been shielded from ‘really bad things’. These are the key events on day 1,189 of Russia’s war on Ukraine.